Jaguar Health, Inc. JAGX
Jaguar Health, Inc. (Nasdaq: JAGX) is a GI/hepatology drug developer. Its lead program, Mytesi (crofelemer 125 mg delayed-release tablets), is in Phase 3 for Symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its next catalyst on record is Crofelemer (OnTarget): Submit final clinical study report to FDA (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Crofelemer (OnTarget) — Submit final clinical study report to FDA (H2 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Mytesi (crofelemer) | HIV-associated non-infectious diarrhea | small molecule | Approved |
| Gelclair (in-licensed from Venture Life) | Oral mucositis pain management | device-combination | Approved |
| Crofelemer powder for oral solution (pivotal pediatric trial) | Microvillus inclusion disease (MVID) | small molecule | Phase 3 |
| Crofelemer (OnTarget Phase 3 completed; planned pivotal trial) | Prophylaxis of cancer-therapy diarrhea in metastatic breast cancer | small molecule | Phase 3 |
| Crofelemer powder for oral solution | Short bowel syndrome with intestinal failure (adult, Phase 2 in Italy/Germany) | small molecule | Phase 2 |
| NP-300 | Cholera / infectious diarrhea | small molecule | Pre-clinical |
| Magdalena Biosciences JV programs (approx 40% owned) | Cognitive impairment associated with schizophrenia | small molecule | Pre-clinical |
| Canalevia-CA1 (animal health, conditional approval) | Chemotherapy-induced diarrhea in dogs | small molecule | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.